MEDICAL SECTOR: diagnostic and therapeutic sensors.
Optoi develops optical devices for diagnostic and therapeutic applications based on specific customer requirements and by collaborating with companies, local, national and international research organizations to develop new products.
The sensors are used in the visible spectrum in analytical equipment and due to the characteristic of being robust to x-rays, γ-rays and protons, they operate in riugh environments ensuring quality results.
The sensors are used in the visible spectrum in analytical equipment and due to the characteristic of being robust to x-rays, γ-rays and protons, they operate in riugh environments ensuring quality results.
OPTICAL DEVICES FOR DIAGNOSTIC IMAGING INSTRUMENTS
X-ray robust sensor assemblies that provide excellent image qualities. We make custom assemblies with scintillators and collimators.
OPTICAL DEVICES FOR RADIOTHERAPY EQUIPMENT
Array of custom optical sensors on gamma-ray radiotherapy machines.
OPTICAL DEVICES FOR ANALYTICAL INSTRUMENTS
Matrix and array of optical sensors for multi-parameter and multi-analytical analysis in fluorescence, chemiluminescence and absorbance at different wavelengths. We make custom solutions with the ability to assemble optical filters and develop multichannel read-out electronics for photoreceivers.
Completed projects
Eurostars
Acronym: proAD Title: microRNA tests for diagnosing preclinical Alzheimer's disease and accelerating drug development. E! 115456 Eurostars CUP C69J21034930004. Optoi in collaboration with the Dutch company TGS develops a binary-response (Y/N) screening test for a diagnosis of sporadic Alzheimer's disease (AS) in patients with subjective cognitive impairment (SCI) or mild cognitive impairment (MCI) and for stratification of patients in clinical trials.
EU funding H2020-MSCA-RISE-2020.
Acronym: diaRNAgnosis. Title: A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids. Consortium leader: DGSL (Spain). GA No 101007934.
An international consortium, led by DESTINA Genomica S.L., combines the transversal skills of companies and universities from Spain, Italy, and the Netherlands. The diaRNAgnosis project aims to create reliable and selective diagnostic tools for detecting circulating cell-free (ccf) RNA in liquid biopsy samples of prostate cancer and germ cell tumours in the testicles.
An international consortium, led by DESTINA Genomica S.L., combines the transversal skills of companies and universities from Spain, Italy, and the Netherlands. The diaRNAgnosis project aims to create reliable and selective diagnostic tools for detecting circulating cell-free (ccf) RNA in liquid biopsy samples of prostate cancer and germ cell tumours in the testicles.
CARITRO FOUNDATION
An innovative diagnostic device for the measurement of microRNAs in liquid biopsies. Consortium leader: University of Trento – CIBIO (Italy).
Optoi has been actively collaborating with the University of Trento – CIBIO for some years now. Thanks to this project, CIBIO, together with the Healthcare Trust of the Autonomous Province of Trento (APSS), will analyse microRNAs as potential predictors of the efficacy of abiraterone in patients with prostate cancer using conventional analytical systems and optical sensors developed by Optoi.
Optoi has been actively collaborating with the University of Trento – CIBIO for some years now. Thanks to this project, CIBIO, together with the Healthcare Trust of the Autonomous Province of Trento (APSS), will analyse microRNAs as potential predictors of the efficacy of abiraterone in patients with prostate cancer using conventional analytical systems and optical sensors developed by Optoi.
EU funding H2020-SC1-BHC-2018-2020.
Acronym: ARREST-TB. Title: Accurate, Rapid, Robust and Economical diagnostic technologies for Tuberculosis. Consortium leader: The University of Edinburgh (UK). GA No 825931.
Optoi is part of an international consortium of universities and companies from Italy, the United Kingdom and Spain, led by the University of Edinburgh and dedicated to the development of diagnostic technologies for tuberculosis, in collaboration with the Research Institute of Tuberculosis in Moscow and with two other reference centres in India that deal with clinical
The ARREST-TB (Accurate, Rapid, Robust and Economical diagnoStic Technologies for Tuberculosis) project aims to develop innovative technologies that can contribute to the early diagnosis of tuberculosis with trials in India and Russia.
Optoi - with its partner DESTINA Genomica - develops an innovative diagnostic system based on optoelectronic sensors and selective chemistry, measuring new generation biomarkers - microRNA - for the early diagnosis and therapeutic monitoring of Tuberculosis.
Optoi is part of an international consortium of universities and companies from Italy, the United Kingdom and Spain, led by the University of Edinburgh and dedicated to the development of diagnostic technologies for tuberculosis, in collaboration with the Research Institute of Tuberculosis in Moscow and with two other reference centres in India that deal with clinical
The ARREST-TB (Accurate, Rapid, Robust and Economical diagnoStic Technologies for Tuberculosis) project aims to develop innovative technologies that can contribute to the early diagnosis of tuberculosis with trials in India and Russia.
Optoi - with its partner DESTINA Genomica - develops an innovative diagnostic system based on optoelectronic sensors and selective chemistry, measuring new generation biomarkers - microRNA - for the early diagnosis and therapeutic monitoring of Tuberculosis.
EU funding H2020 Marie-Curie Actions
Acronym: miRNA-DisEASY. Title: microRNA biomarkers in an innovative biophotonic sensor kit for high-specific diagnosis. Consortium leader: OPTOI Srl. (Italy). GA No 690866.
A multidisciplinary and cross-sectoral consortium, led by Optoi, synergistically involved companies and academic institutions in Germany, Spain, Italy and Brazil with mutual exchange of highly qualified personnel. The research activity has generated a stimulating scientific and technological environment preparatory to the generation of new ideas and technological solutions in the field of lung cancer diagnosis.
As part of the miRNA-DisEASY project, Optoi has developed a device alongside a revolutionary chemical technology aimed at simplifying and making more reliable the detection of circulating biomarkers, providing valuable support to medical personnel.
At the end of the project, OPTOI was awarded the title “key innovators” by the Innovation Radar initiative sponsored by the European Commission.
A multidisciplinary and cross-sectoral consortium, led by Optoi, synergistically involved companies and academic institutions in Germany, Spain, Italy and Brazil with mutual exchange of highly qualified personnel. The research activity has generated a stimulating scientific and technological environment preparatory to the generation of new ideas and technological solutions in the field of lung cancer diagnosis.
As part of the miRNA-DisEASY project, Optoi has developed a device alongside a revolutionary chemical technology aimed at simplifying and making more reliable the detection of circulating biomarkers, providing valuable support to medical personnel.
At the end of the project, OPTOI was awarded the title “key innovators” by the Innovation Radar initiative sponsored by the European Commission.
Publications and awards
- Detassis et al., SA-ODG platform: a semi-automated and PCRfree method to analyse microRNAs in solid tissues, Analyst, 2024, 149, 3891.
- E Garcia-Fernandez, et. al. miR-122 direct detection in human serum by time-gated fluorescence imaging. Chemical Communications, 2019, 55 (99), 14958-14961.
- S Detassis, et. al. New Platform for the Direct Profiling of microRNAs in Biofluids. Analytical Chemistry, 2019, 91 (9), 5874-5880.
- S Detassis, et. al. New Platform for the Direct Profiling of microRNAs in Biofluids. Best Poster Award at the Oligonucleotide Therapeutic Society annual meeting, 2019.